Literature DB >> 1325210

Restoration of superoxide generation to a chronic granulomatous disease-derived B-cell line by retrovirus mediated gene transfer.

A Thrasher1, M Chetty, C Casimir, A W Segal.   

Abstract

Failure of a superoxide generating system, the NADPH oxidase, present in neutrophils and other phagocytes gives rise to chronic granulomatous disease (CGD), a group of single-gene inherited disorders all characterized by an extreme susceptibility to pyogenic infection, with potentially fatal consequences. About 30% of CGD cases are caused by an autosomally inherited deficiency of a 47-Kd cytoplasmic component of the oxidase (p47-phox). Epstein-Barr virus (EBV) immortalized B-lymphocyte lines established from these CGD patients also express this NADPH oxidase defect and consequently are rendered incapable of generating superoxide on stimulation. We have used a p47-phox-deficient EBV-transformed B-cell line as a recipient for retroviral transfer of a functional p47-phox cDNA. The presence and activity of the retrovirally encoded p47-phox in the transduced cells is demonstrated and we show that this restores their capacity to generate superoxide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325210

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Production of extracellular superoxide by human lymphoblast cell lines: comparison of electron spin resonance techniques and cytochrome C reduction assay.

Authors:  Sergey I Dikalov; Wei Li; Payam Mehranpour; Shaoshan S Wang; A Maziar Zafari
Journal:  Biochem Pharmacol       Date:  2006-12-15       Impact factor: 5.858

2.  Superoxide generation in transformed B-lymphocytes from patients with severe, malignant osteopetrosis.

Authors:  S Yang; W L Ries; L L Key
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

3.  Low NADPH oxidase activity in Epstein-Barr-virus-immortalized B-lymphocytes is due to a post-transcriptional block in expression of cytochrome b558.

Authors:  M Chetty; A J Thrasher; A Abo; C M Casimir
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

4.  Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox.

Authors:  L Zhen; A A King; Y Xiao; S J Chanock; S H Orkin; M C Dinauer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

5.  Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease.

Authors:  S Sekhsaria; J I Gallin; G F Linton; R M Mallory; R C Mulligan; H L Malech
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

6.  The phosphorylation targets of p47phox, a subunit of the respiratory burst oxidase. Functions of the individual target serines as evaluated by site-directed mutagenesis.

Authors:  L R Faust; J el Benna; B M Babior; S J Chanock
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Phosphorylation of p47phox is required for receptor-mediated NADPH oxidase/NOX2 activation in Epstein-Barr virus-transformed human B lymphocytes.

Authors:  Sahra Amel Belambri; Margarita Hurtado-Nedelec; Abderrahmane Senator; Karama Makni-Maalej; Michèle Fay; Marie-Anne Gougerot-Pocidalo; Jean-Claude Marie; Pham My-Chan Dang; Jamel El-Benna
Journal:  Am J Blood Res       Date:  2012-10-20

8.  Effect of the Salmonella pathogenicity island 2 type III secretion system on Salmonella survival in activated chicken macrophage-like HD11 cells.

Authors:  Amanda L S Wisner; Andrew A Potter; Wolfgang Köster
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

9.  Chronic Granulomatous Disease; fundamental stages in our understanding of CGD.

Authors:  Tracy Assari
Journal:  Med Immunol       Date:  2006-09-21

Review 10.  Genetics and immunopathology of chronic granulomatous disease.

Authors:  Marie José Stasia; Xing Jun Li
Journal:  Semin Immunopathol       Date:  2008-05-29       Impact factor: 11.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.